The SAS "Special Access Scheme" for the Australian market is interesting. I don't fully understand why, if you can access Oncosil through the SAS even if you cannot advertise it, it would not have TGA approval in Australia. Does anyone know how to better explain it? Can anyone enlighten me?
Ann: 2021 AGM CEO Presentation, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $41.62M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $34.82K | 3.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 6856710 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 2741527 | 4 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |